 Allergan Inc. on Tuesday rejected a sweetened $53 billion bid from Valeant Pharmaceuticals International Inc. and William Ackman and said it still wouldn't enter into negotiations.. The Irvine, Calif., maker of Botox said Valeant's cash-and-stock offer significantly undervalues its prospects for growth. It again called Valeant's business model "unsustainable" and said Allergan shareholders don't want Valeant stock.. "They...
  